A recent study indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt traditional lifestyle plans.
Research printed in a prominent medical journal shows that while obese individuals often shed substantial amounts of their body weight while using the jabs, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Users purchasing these medications must be cognizant of the potential of rapid rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment weight within about a year and a half.
Analyzing Therapies
The research, which examined dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers point out that individuals who lose weight through diet and exercise generally have a slower weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Nutrition scientists suggest the way of the jabs explains the heightened weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication means appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Issue?
The NHS recommend the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
Many experts say that, given the high risk of relapse, the treatment might need to be long-term.
This opinion is echoed by pharmaceutical companies, who say that the findings "emphasize the long-term character of obesity," comparing it to managing conditions like hypertension.
User Accounts
People who have stopped the medication describe a powerful resurgence of appetite.
"It felt as if a trigger that goes on and you're instantly extremely hungry," described an individual.
The struggle is compounded if individuals have not developed sustainable lifestyle or habit changes during treatment.
Widespread Adoption
Survey data show that a significant number of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Use is greater among females compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic cure and maintained weight loss hinges on combined lifestyle support.
